Besides the potential for measures of LRRK2 and its Rab substrates as biomarkers in PD, the phosphorylation of LRRK2 and Rab proteins are also proposed biomarkers of pharmacological response to treatment with LRRK2 kinase inhibitors. This evidence concerns the gene AGFG1 and Parkinson disease.